Responsible for development, leading engagement teams and project execution and deliverables in the following key areas:

1) Corporate and commercialization strategy including go-to-market, market access and pricing strategy

2) Corporate finance including M&A, joint ventures and licensing

3) Program and project management of key strategic initiatives

Responsible for a cross-functional team of over 30 to define, develop and implement company-wide strategic and business unit planning using a balanced scorecard system.

Selected as a member of the Millennium Product and Pipeline Management (MPPM) Steering Committee.

Responsible for leading and developing multiple franchise, marketing and branding strategies for leading pharmaceutical companies in core therapeutic areas such as Oncology, Neurology, Cardiovascular and Rare Diseases.

Led the development of an R&D decision support system (dashboard) for a top 10 pharmaceutical company subsidiary with an R&D budget in excess of $800M.

Responsible for leading project teams in development of US marketing and pricing and reimbursement strategies for major products in inflammatory, metabolic, cardiovascular and antibiotic therapeutic areas.

Responsible for execution of major key thought leader research programs and the development novel pricing strategies that enabled multiple products to achieve revenue in excess of $1B.

Led the Portfolio Management Group and evaluated Merck’s R&D development product portfolio ($2.5B+) utilizing the Research Planning Model (featured in Harvard Business Review and Fortune).

Selected as a core team member of commercialization teams for major Merck development programs.

Responsible for corporate finance valuation and analysis. Participated in multiple corporate finance transactions involving over $7 billion in assets and made recommendations to Corporate Development & Licensing and senior finance management on proposed deal structures and terms.

Responsible for evaluation of strategic initiatives, competitive analysis and cost restructuring.

Developed a strategic assessment of the biotechnology industry that recommended increasing Merck’s involvement in biotechnology and the use of equity arrangements in early-stage technology deals.

Successfully modeled strategic scenarios and developed the key findings that led to a $775 million restructuring.